•
Mar 31, 2024

Stryker Q1 2024 Earnings Report

Stryker reported a strong first quarter with significant growth in net sales and earnings.

Key Takeaways

Stryker's Q1 2024 results showed a 9.7% increase in reported net sales to $5.2 billion and a 10.0% increase in organic net sales. The company's reported EPS increased by 33.1% to $2.05, and adjusted EPS increased by 16.8% to $2.50. Management is confident in the company's ability to grow sales and drive strong adjusted earnings growth in 2024.

Reported net sales increased by 9.7% to $5.2 billion.

Organic net sales increased by 10.0%.

Reported EPS increased by 33.1% to $2.05.

Adjusted EPS increased by 16.8% to $2.50.

Total Revenue
$5.24B
Previous year: $4.78B
+9.7%
EPS
$2.5
Previous year: $2.14
+16.8%
Organic Net Sales Growth
10%
Previous year: 13.6%
-26.5%
Gross Profit
$3.33B
Previous year: $3.02B
+10.5%
Cash and Equivalents
$2.33B
Previous year: $1.67B
+39.4%
Free Cash Flow
$37M
Previous year: $315M
-88.3%
Total Assets
$39.4B
Previous year: $36.8B
+7.0%

Stryker

Stryker

Stryker Revenue by Geographic Location

Forward Guidance

Stryker now expects full year 2024 organic net sales growth to be in the range of 8.5% to 9.5% and adjusted net earnings per diluted share to be in the range of $11.85 to $12.05.

Positive Outlook

  • Strong procedural volumes
  • Healthy demand for capital products
  • Commitment to expanding operating margins

Challenges Ahead

  • Foreign exchange rates will moderately unfavorably impact net sales for the full year.
  • Adjusted net earnings per diluted share will be negatively impacted at the higher end of our previously guided range of $0.05 to $0.10 for the full year.

Revenue & Expenses

Visualization of income flow from segment revenue to net income